Long-term real-world safety and effectiveness of arimoclomol in individuals with NPC: Outcomes from the US early access program over a 4-year period

Study limitation reported by the research below: “The Year 4 subgroup (n=22) is much smaller than Baseline (n=100), which may reflect dropout, mortality, or loss to follow-up — survivorship bias cannot be excluded.”